443.64
Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース
Alnylam Pharmaceuticals' Insider Sales: Compliance-Driven Moves or Subtle Signals of Strategic Shift? - AInvest
Alnylam Pharmaceuticals: Insider Selling as a Signal of Discipline, Not Distrust - AInvest
Insider Selling at Alnylam Pharmaceuticals: A Closer Look at Implications for Investors - AInvest
Alnylam EVP Garg sells $1.3 million in stock - Investing.com
Three Companies That Might Be Priced Below Their Estimated Value - simplywall.st
Insider Selling at Alnylam Pharmaceuticals: Profit-Taking or a Warning Sign? - AInvest
Alnylam Shares Surge on $730M Volume After FDA Approval Boosts Market Outlook and Analysts Raise Targets - AInvest
Why Alnylam Pharmaceuticals Inc. stock attracts strong analyst attentionWall Street Watch & Scalable Portfolio Growth Ideas - beatles.ru
Alnylam Pharmaceuticals, Inc. (ALNY) Gets EU Nod for AMVUTTRA - MSN
Alnylam Pharmaceuticals’ SWOT analysis: stock poised for growth amid ATTR-CM market expansion - Investing.com
Free Genetic Tests May Aid People With Rare Kidney Disease - Medscape
Insider Selling Trends in Nasdaq-Listed Companies: A Cautionary Lens on Alnylam, Boston Scientific, and CSX - AInvest
Alnylam, Halozyme among latest firms to win EU backing for drugs - MSN
Alnylam Pharmaceuticals Inc. Reversal Rally May Surprise Bears2025 Market Overview & Technical Buy Zone Confirmations - beatles.ru
Alnylam Pharmaceuticals stock hits all-time high at 445.44 USD By Investing.com - Investing.com Australia
Alnylam Pharmaceuticals stock hits all-time high at 445.44 USD - Investing.com
Alnylam Gains 2.36% on FDA Support and Buy Rating as Top 500 Volume Strategy Yields 31.52% Return - AInvest
Alnylam Raises 2025 Revenue Guidance as Losses Widen Might Change The Case For Investing In ALNY - simplywall.st
Alnylam’s Trading Volume Surges 38.6% to Rank 113th in Market Activity - AInvest
Promising Biotech Stocks Worth WatchingAugust 12th - MarketBeat
Here's How Much $100 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today - 富途牛牛
Why Alnylam Pharmaceuticals Inc. stock attracts strong analyst attention [2025 Valuation Update]Low Risk Entry Point Tips - sisaissue.com
Alnylam’s $650M Volume Ranks 168th as Shares Drop 1.17% Pre-ESC Data Presentation - AInvest
Alnylam at Canaccord Genuity: Strategic Growth and Innovation By Investing.com - Investing.com Nigeria
Alnylam at Canaccord Genuity: Strategic Growth and Innovation - Investing.com
Alnylam’s Vutrisiran Study: A Potential Game-Changer for Cardiomyopathy Treatment - TipRanks
Alnylam Pharmaceuticals at Canaccord Genuity's 45th Annual Growth Conference - AInvest
Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025 - BioSpace
Profits May Be Just Around the Corner for This Strong-Buy Pharma Stock - Yahoo Finance
Possible Bearish Signals With Alnylam Pharmaceuticals Insiders Disposing Stock - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Is Up 9.2% After Upward Q2 Revenue Guidance Revision and Higher Analyst Forecasts—Has the Bull Case Changed? - simplywall.st
Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress - ADVFN Brasil
Alnylam Gains 1.63% on Surging Amvuttra Sales Hits 233rd in Market Activity - AInvest
Alnylam Pharma: Strong Commercial Performance and Promising Pipeline Drive Buy Rating - TipRanks
Does Alnylam’s (ALNY) Upbeat Revenue Forecast Signal Shifting Momentum in Its Long-Term Growth Story? - simplywall.st
Vir (VIR) Q2 Revenue Drops 61% - The Motley Fool
Alnylam Rises 2.2% on 17% Revenue Surge and Analyst Upgrades Despite 220th-Ranked 0.5B Volume Drop - AInvest
Alnylam Pharmaceuticals stock hits all-time high at $427.0 USD - Investing.com
Alnylam Pharmaceuticals stock hits all-time high at $427.0 USD By Investing.com - Investing.com Canada
Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share - BioPharma Dive
Alnylam Slips 0.15% Despite $760M Volume Ranking 137th in U.S. Equities as Mixed Pipeline Data Weigh on Momentum - AInvest
Alnylam’s Amvuttra Sales Leave Forecasts In The Dust - Finimize
Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference - Business Wire
Alnylam Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - simplywall.st
Analyst Forecasts For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Are Surging Higher - Yahoo Finance
U.S. Transthyretin Amyloidosis Treatment Market Exclusive - openPR.com
Health Care Stocks See Gains On Strong Results And Approvals - Finimize
Wolfe Research upgrades Alnylam Pharmaceuticals stock rating to Peerperform By Investing.com - Investing.com Canada
Oppenheimer upgrades Alnylam stock to Outperform on strong Amvuttra sales By Investing.com - Investing.com Canada
Earnings Estimates Rising for Alnylam (ALNY): Will It Gain? - Yahoo Finance
Alnylam Pharmaceuticals Surges 3.79% Intraday – What’s Fueling This Sudden Rally? - AInvest
Alnylam's Amvuttra Sales Exceeding Expectations by Sizable Margin, Oppenheimer Says - MarketScreener
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? - Yahoo Finance
This Alnylam Pharmaceuticals Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday - Benzinga
Why Alnylam Pharmaceuticals (ALNY) Is Up 23.7% After Raising 2025 Revenue Outlook on AMVUTTRA Growth - simplywall.st
What are analysts’ price targets for Alnylam Pharmaceuticals Inc. in the next 12 monthsTremendous growth potential - Jammu Links News
When is Alnylam Pharmaceuticals Inc. stock expected to show significant growthDiscover top stock picks for aggressive growth - Jammu Links News
How does Alnylam Pharmaceuticals Inc. compare to its industry peersUnmatched market performance - Jammu Links News
What are the latest earnings results for Alnylam Pharmaceuticals Inc.Free Capital Efficiency Planning - Jammu Links News
Does Alnylam Pharmaceuticals Inc. stock perform well during market downturnsCapitalize on momentum-driven investment opportunities - Jammu Links News
How does Alnylam Pharmaceuticals Inc. generate profit in a changing economyConsistently superior profits - Jammu Links News
What makes Alnylam Pharmaceuticals Inc. stock price move sharplyUnlock powerful stock screening tools today - Jammu Links News
How volatile is Alnylam Pharmaceuticals Inc. stock compared to the marketCapitalize on strong market momentum - Jammu Links News
大文字化:
|
ボリューム (24 時間):